RECENT PLACEMENT

Occam Places Leo Wossnig as CTO of LabGenius

Occam Places Leo Wossnig as CTO of LabGenius

Occam’s enduring relationship with LabGenius, a UK-based AI-enabled protein drug discovery platform company, has yielded a second C-suite placement in Leo Wossnig, PhD as Chief Technology Officer. Leo will work in close partnership with Gino Van Heeke, the CSO, whom Occam placed as CSO in 2021.

‍

Wossnig comes to LabGenius by way of Odyssey Therapeutics following the acquisition of his company, Rahko, a leading quantum machine learning company which Leo co-founded and led as CEO.

‍

In Wossnig, LabGenius captures an intellectual heavyweight, content expert and accomplished entrepreneur with demonstrated success building and leveraging sophisticated computational technologies in the service of expediting drug discovery at scale

‍

Read more about Occam's other recent placements for LabGenius:

CSO: Gino Van Heeke, PhD

CBO: Hannah Seitz, PhD

‍

Related Placements

  1. Suzanne “Sue” Bruhn CEO of Prominent Rare Disease Research Foundation
  2. Vatnak Vat-Ho as CBO at Ryvu Therapeutics
  3. Steve Colletti as CSO of Korro Bio
  4. Theo Karaletsos as VP, Data Science/ML at insitro
  5. Sana Hafeez as Head of People at Unlearn
About Occam Global

Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.